Contract research organisation (CRO) GVK Biosciences recently announced it has signed a material transfer deal with the Genomics group of the US Food and Drug Administration (FDA) to share information from its Clinical Biomarker Database. The Genomics group will use the database in its voluntary genomics data submission (VGDS) as well as in its internal research. India-based GVK will use the FDA's feedback to further optimise the content and capabilities of the database which currently contains over 278 different fields for clinically reported biomarkers. Meanwhile, Canada's Lab Research has completed the expansion of its Danish site. The non-clinical CRO said the expansion will boost the site's large animal housing capacity by more than 50 per cent. Also in the news recently was GATC Biotech - a sequencing service provider - who announced the acquisition of a SOLID DNA sequencing system from Applied Biosystems for €2m. The new system will be the third next generation sequencing technology to be installed in GATC's German research facility, which currently includes technologies from Roche Diaganostics and Illumina. The new system is expected to be installed in early autumn this year and will boost the company's current sequencing capacity from 130 gigabases to 250 gigabases a year. GATC will then be the only commercial sequencing service provider worldwide to offer ultra high-throughput DNA analysis using all three leading next generation sequencing technologies. Finally, Bridge Pharmaceuticals announced last week received full recognition from the international animal care accreditation body for its facility in Beijing, China. Bridge's site - Vital Bridge - is one of only seven toxicology facilities in the country to receive this recognition from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Bridge said that more than 30 countries recognize AAALAC accreditation as a proof of responsible, ethical lab animal care. The US-based company is one of the first preclinical CROs to provide US-level drug development services in both Asia and the US.